Hogan Lovells advised EyePoint Pharmaceuticals on the offering.Eyepoint Pharmaceuticals, Inc. (NASDAQ: EYPT), a clinical-stage biopharmaceutical company, announced its US$161 million follow-on public offering of 14,636,363 shares…
EyePoint Pharmaceuticals, Inc.’s US$161 Million Public Offering Of Common Stock
